Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.
Latest updates
November 14, 2022
Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer
Boston, MA & Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16...
Platform
A-KINE™ PLATFORM
Reprogramming cell targets
Conditional modulation of cell functions to trigger therapeutic effects using cytokines with tuned-out off-target interactions and sites of action that are focused on intended disease targets.
Platform
ALLO-GLUE™ PLATFORM
Reprogramming protein targets
Altering form and function of intracellular proteins to induce them to engage in molecular interactions that promote inhibition of disease targets previously thought unapproachable.
Pipeline
Pipeline
Reprogramming the cancer immunity cycle
Overcoming immunosuppressive tumor microenvironments to unleash targeted immune system attack on human cancers and promote immunity.
Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.
Latest updates
A-KINE™ PLATFORM
ALLO-GLUE™ PLATFORM
Pipeline
Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer
November 14, 2022
Boston, MA & Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16...
Reprogramming cell targets
Conditional modulation of cell functions to trigger therapeutic effects using cytokines with tuned-out off-target interactions and sites of action that are focused on intended disease targets.
Learn moreReprogramming protein targets
Altering form and function of intracellular proteins to induce them to engage in molecular interactions that promote inhibition of disease targets previously thought unapproachable.
Learn moreReprogramming the cancer immunity cycle
Overcoming immunosuppressive tumor microenvironments to unleash targeted immune system attack on human cancers and promote immunity.
Learn more